About
Technology
Issues
FAQ
Links
Official Page
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.